drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy
drug_description
Autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy; gene-modified T cells target CD19+ B cells/plasmablasts to induce B-cell aplasia and reset humoral immunity.
nci_thesaurus_concept_id
C175465
nci_thesaurus_definition
A preparation of autologous T-lymphocytes that are engineered to express a chimeric antigen receptor (CAR) composed of an anti-cluster of differentiation 19 (CD19) single chain variable fragment (scFv) linked to the intracellular signaling domains of 4-1BB (CD137) and the zeta chain of the TCR/CD3 complex (TCRzeta; CD247; CD3zeta), with potential immunomodulating and antineoplastic activities. Upon administration, the autologous anti-CD19 CAR-4-1BB-CD3zeta-expressing T-cells CNCT19 target, bind to and induce selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells engineered to express an anti-CD19 chimeric antigen receptor with 4-1BB and CD3zeta signaling domains bind CD19 on B cells/plasmablasts and induce targeted cytotoxicity, causing B-cell aplasia and resetting humoral immunity (also cytotoxic to CD19+ tumor cells).
drug_name
CNCT19
nct_id_drug_ref
NCT05930314